Nikoletta L Kallinteris - JoVE Visualize

Showing results (1-10 of 16) with videos related to

Pageof 2

Sort By:

Vaccine|March 6, 2012

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccinesMinzhen Xu, Nikoletta L Kallinteris, Eric von Hofe

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005

Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitopeNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Vaccine|March 10, 2005

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodiesNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Expert Opinion on Biological Therapy|January 17, 2007

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccinesNikoletta L Kallinteris, Xueqing Lu, Catherine E Blackwell, et al.

Cancer Immunology, Immunotherapy : CII|January 24, 2004

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancerMichael E Gillogly, Nikoletta L Kallinteris, Minzhen Xu, et al.

Cancer|February 27, 2010

A new era in anticancer peptide vaccinesSonia A Perez, Eric von Hofe, Nikoletta L Kallinteris, et al.

Vaccine|September 25, 2003

Ii-Key/MHC class II epitope hybrid peptide vaccines for HIVNikoletta L Kallinteris, Xueqing Lu, Shuzhen Wu, et al.

International Journal of Cancer|July 20, 2007

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chainIoannis F Voutsas, Angelos D Gritzapis, Louisa G Mahaira, et al.

Current Opinion in Molecular Therapeutics|June 16, 2004

Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II moleculesMinzhen Xu, Xueqing Lu, Nikoletta L Kallinteris, et al.

Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2005

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious diseaseNikoletta L Kallinteris, Douglas Powell, Catherine E Blackwell, et al.

Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:

Pageof 2

Vaccine|March 6, 2012

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccinesMinzhen Xu, Nikoletta L Kallinteris, Eric von Hofe

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005

Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitopeNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Vaccine|March 10, 2005

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodiesNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Expert Opinion on Biological Therapy|January 17, 2007

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccinesNikoletta L Kallinteris, Xueqing Lu, Catherine E Blackwell, et al.

Cancer Immunology, Immunotherapy : CII|January 24, 2004

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancerMichael E Gillogly, Nikoletta L Kallinteris, Minzhen Xu, et al.

Cancer|February 27, 2010

A new era in anticancer peptide vaccinesSonia A Perez, Eric von Hofe, Nikoletta L Kallinteris, et al.

Vaccine|September 25, 2003

Ii-Key/MHC class II epitope hybrid peptide vaccines for HIVNikoletta L Kallinteris, Xueqing Lu, Shuzhen Wu, et al.

International Journal of Cancer|July 20, 2007

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chainIoannis F Voutsas, Angelos D Gritzapis, Louisa G Mahaira, et al.

Current Opinion in Molecular Therapeutics|June 16, 2004

Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II moleculesMinzhen Xu, Xueqing Lu, Nikoletta L Kallinteris, et al.

Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2005

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious diseaseNikoletta L Kallinteris, Douglas Powell, Catherine E Blackwell, et al.

Pageof 2